Urothelial Cancer

When you consider how complex the system is, and how little training physicians get in medical school about coding, it stands to reason that practice leadership must emphasize its importance.

It is with great pleasure that I welcome you to the inaugural issue of Urologists in Cancer Care.

Investigators have documented gross under-use of established recommendations for the management of high-grade noninvasive bladder cancer.

An interview with Neal D. Shore, MD, discussing expanding the scope of cystoscopy and the optical imaging agent Cysview.

Study results reveal that only a small fraction of patients with high-grade, noninvasive bladder cancer receive the appropriate treatment.

Dr. Cella From Northwestern University Feinberg School of Medicine Discusses Axitinib and Sorafenib Axis Trial

The FDA announced that the prolonged use of pioglitazone (Actos) for more than 1 year has been linked to an increased risk of bladder cancer

Dr. Robert Alter on Current Research at John Theurer Cancer Center

Robert S. Alter, MD, Co-chief, Urologic Oncology, John Theurer Cancer Center, on kidney cancer drugs from the year 2005 to 2010.

Fast biotech facts and figures. In this issue: 1) Cancer Risk Factors and Mortality 2) Bladder Cancer 3) Testicular Cancer 4) Breast Cancer